Aclaris Therapeutics Raises $39.8M via ATM Offering, Diluting Shares by 12.7M
Summary
Aclaris Therapeutics has successfully sold 12.7 million shares of common stock through an at-the-market (ATM) offering, generating gross proceeds of $39.8 million. This capital raise, which occurred between March 2 and March 9, 2026, follows the company's recent increase in authorized common stock to 400 million shares, as reported in its February 26, 2026 10-K filing. The proceeds are intended to bolster the company's liquidity and support general corporate needs. While the offering provides Aclaris with significant capital, representing nearly 10% of its current market capitalization, it also results in notable share dilution for existing shareholders. Traders will monitor how this new capital is deployed and its impact on the company's financial trajectory.
At the time of this announcement, ACRS was trading at $3.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $408.8M. The 52-week trading range was $1.05 to $4.89. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.